Tools chosen: kalshi_direct claude_news gdelt_news wikipedia kalshi_related polymarket_related

Sub-questions (Fermi decomposition)

Planner reasoning

This is a global health question about wild poliovirus type 1 elimination. Key drivers are current case counts in endemic countries (Pakistan, Afghanistan), yearly trends, and vaccination campaign progress. The market price anchors consensus, and current WHO/GPEI data will inform whether a zero-case year is plausible by 2029.

# Current state The market resolves Yes if ANY single calendar year from 2024–2029 records zero WPV1 cases globally. 2024 recorded 99 WPV1 cases; 2025 is tracking lower (13 cases as of ~July 2025) but both endemic countries (Pakistan, Afghanistan) continue active transmission. 2026 GDELT data already shows ongoing cases in both countries. # Timeline of key events - **2016**: Nigeria's last wild polio case — only Pakistan and Afghanistan remain endemic [Wikipedia, confirmed] - **2019**: WPV3 declared eradicated [Wikipedia, confirmed] - **2023**: Relatively lower WPV1 case count (implied by ~12x Pakistan surge in 2024) [WHO, confirmed] - **2024**: 99 WPV1 cases globally — Pakistan 74, Afghanistan 25; 741 WPV1-positive environmental samples [WHO IHR EC 41, confirmed] - **2024-10**: GPEI Polio Oversight Board approves Strategy Extension to 2029, extending eradication timeline [GPEI, confirmed] - **2025-04-10**: WHO IHR EC 41st meeting — 2025 YTD cases already accumulating; cross-border migration flagged as compounding risk [WHO, confirmed] - **2025-07-28**: WHO IHR EC 42nd meeting — global 2025 total at 13 WPV1 cases (1 Afghanistan, 8+ Pakistan) [WHO, confirmed] - **2026-04 to 06**: GDELT reports ongoing WPV1 cases in Pakistan and Afghanistan throughout 2026; Afghanistan total rising to 6 by June 2026 [GDELT, reported] --- # Event Will any calendar year 2024–2029 record zero reported wild poliovirus type 1 cases globally? # Outcomes to forecast - **Yes**: At least one year in 2024–2029 has zero WPV1 cases - **No**: Every year 2024–2029 has at least one WPV1 case # Kalshi market anchor **Current YES price: 5.80%** (as of ~45 days of data). 7-day change: −1.60%; 30-day change: +1.50%. Price range over period: 4.00%–10.40%. Volume: ~272 contracts/day. Market has drifted slightly lower recently, consistent with 2026 case data confirming ongoing transmission. # Sub-question answers 1. **WPV1 cases in 2024 and 2025?** — 2024: 99 cases (Pakistan 74, Afghanistan 25). 2025: 13 cases as of ~July 2025 (1 Afghanistan, 8+ Pakistan per latest WHO update). [WHO IHR EC 41 & 42] 2. **Multi-year trend in Pakistan and Afghanistan?** — Both countries saw >4x (Afghanistan) and >12x (Pakistan) surges from 2023 to 2024. 2025 is tracking sharply lower but environmental samples remain extensive (80 WPV1-positive through March 2025). [WHO IHR EC 41] 3. **Has any year come close to zero? What disrupted it?** — No year in the WPV1-only era has come close to zero; cases have fluctuated but never dropped below single digits. COVID-19 disrupted campaigns in 2020 causing resurgences; conflict and access issues have repeatedly set back progress. [Wikipedia, WHO] 4. **GPEI/WHO eradication projections?** — Official target was WPV1 interruption and certification by 2027 (cVDPV2 by 2029), but GPEI extended its strategy to 2029 in Oct 2024, acknowledging the initiative is "at a crossroads." [GPEI, confirmed] 5. **Major obstacles to zero-case year before 2030?** — Yes: active conflict/insecurity in KP and Balochistan (Pakistan), Taliban access restrictions (Afghanistan), ~200K missed children per campaign in South KP alone, cross-border migration, declining GPEI funding in 2025, ongoing environmental detections far exceeding clinical cases. [WHO IHR EC 41, NCBI] # Key facts (high-confidence, factual) 1. [WHO] 2024: 99 WPV1 cases globally, highest in several years 2. [WHO] 2025 YTD (~July): 13 WPV1 cases — significant improvement but not zero 3. [GDELT/reported] 2026 shows continued cases in both Pakistan and Afghanistan (Afghanistan at 6 by June 2026) 4. [Wikipedia] WPV2 eradicated 2015, WPV3 eradicated 2019; only WPV1 remains 5. [GPEI] Eradication timeline officially extended to 2029; initiative acknowledges "new approaches needed" 6. [NCBI] Funding cuts in 2025 are an acute threat to progress 7. [WHO] Environmental surveillance (WPV1+ samples) greatly exceeds clinical case counts, indicating widespread subclinical circulation # Cross-market signals - **Kalshi related**: Only one relevant market found (this one, KXPOLIOELIM-30 at 5.80%) - **Polymarket**: No matching markets found - **Sportsbook**: N/A # Analyst opinions and speculation - WHO IHR Emergency Committee implicitly signals low confidence in near-term eradication by extending timelines and labeling initiative at a "crossroads" [GPEI] - 2025's sharp case-count decline vs. 2024 is modestly encouraging, but environmental samples show virus still circulating widely [WHO IHR EC 41] - Funding shortfalls in 2025 could reverse gains [NCBI] - Pakistan described as "key reservoir" in 2026 reporting [GDELT] # Directional lean per outcome - **Yes (zero-case year)**: 2025 case count is substantially lower (~13 vs 99); trend theoretically could reach zero by 2027–2028 if sustained. GPEI target of interruption by 2027 is still nominally live. - **No**: 2026 already has confirmed cases in both countries; environmental detections far exceed clinical cases (virus circulating widely); GPEI itself extended timeline acknowledging difficulty; funding cuts; structural access barriers in Taliban-controlled Afghanistan and conflict zones in Pakistan; no precedent for sudden collapse to zero. # Gaps / unknowns - Full 2025 annual case count not yet finalized - Extent of 2025 funding cuts and operational impact - Whether Taliban-GPEI access agreements will improve - Whether a novel intervention (e.g., new vaccine formulation, outbreak response surge) could dramatically accelerate progress # Calibration anchors - **Kalshi current YES price: 5.80%** (primary anchor) - Precedent: WPV2 and WPV3 eradication took decades after case counts dropped to very low levels; certification required 3 years of zero cases after last detection - 2026 GDELT data already rules out 2026 as a zero-case year, leaving only 2027–2029 (3 years remaining) - Given ongoing 2026 transmission and structural barriers, ~5–7% YES seems well-calibrated; slight upward pressure from 2025's improved trajectory, offset by 2026 confirmation of continued transmission

1. Both forecasters treat 2026 as definitively ruled out based on GDELT-reported cases, but the brief flags GDELT as "reported" rather than WHO-confirmed, and the 2025 full-year count is still unknown — if 2025 ends at or near zero (13 cases by July is very low), this possibility deserves slightly more weight than either forecaster gives it. 2. Neither forecaster quantifies the conditional probability of zero given only 3 remaining eligible years (2027–2029), nor does either engage with the base rate of how quickly WPV1 declined in the final phases of WPV2/WPV3 eradication — those precedents suggest a near-zero year can arrive quickly once case counts reach single digits, which is a scenario the brief raises but both forecasters under-weight. 3. Both forecasters lean heavily on the Kalshi anchor (5.8%) without independently stress-testing it; the brief itself notes the price range was 4%–10.4%, suggesting genuine market uncertainty, yet neither forecaster explores whether the lower end (4%) or upper end (10.4%) might be more appropriate given the 2026 confirmation of ongoing transmission. 4. The environmental surveillance signal — "741 WPV1-positive environmental samples in 2024" and "80 through March 2025" — is cited but neither forecaster explicitly integrates this as evidence that clinical cases undercount true circulation by orders of magnitude, which is the strongest structural argument against a sudden zero-case year and deserves more explicit weight. 5. Neither forecaster addresses the asymmetric impact of the 2025 funding cuts: the brief notes this is an "acute threat" that could reverse 2025 gains, yet both treat the 2025 downward trend as a mild positive signal without discounting it for the probability that funding deterioration produces a 2025 resurgence in the second half of the year. 6. Forecaster 1 claims "high confidence" despite anchoring almost entirely on the Kalshi price and the same evidence as Forecaster 2, whose confidence is "medium" — the high-confidence label for Forecast 1 is unjustified given the acknowledged unknowns (Taliban access, funding impact, novel interventions) that both forecasters explicitly recognize but do not model.

5% (65% confidence)

Yes: 5% No: 95%

2024 (99), 2025 (13+), and 2026 (confirmed ongoing) are already nonzero, leaving only 2027-2029. Extensive environmental circulation, access/conflict barriers, and funding cuts make a sudden collapse to zero unlikely. The Kalshi anchor of 5.8% is well-calibrated; I settle at 5%, consistent with both forecasts.

Total pipeline time: 127.6s